GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Leap Therapeutics Inc (NAS:LPTX) » Definitions » Cyclically Adjusted Book per Share

Leap Therapeutics (Leap Therapeutics) Cyclically Adjusted Book per Share : $7.00 (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Leap Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Leap Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was $1.850. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $7.00 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Leap Therapeutics's average Cyclically Adjusted Book Growth Rate was -8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-05), Leap Therapeutics's current stock price is $2.345. Leap Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $7.00. Leap Therapeutics's Cyclically Adjusted PB Ratio of today is 0.34.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Leap Therapeutics was 1.13. The lowest was 0.17. And the median was 0.42.


Leap Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Leap Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Leap Therapeutics Cyclically Adjusted Book per Share Chart

Leap Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 7.64 7.15

Leap Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.62 7.58 7.52 7.15 7.00

Competitive Comparison of Leap Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Leap Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Leap Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Leap Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Leap Therapeutics's Cyclically Adjusted PB Ratio falls into.



Leap Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Leap Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=1.85/131.7762*131.7762
=1.850

Current CPI (Mar. 2024) = 131.7762.

Leap Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 7.125 100.560 9.337
201409 32.752 100.428 42.975
201412 28.416 99.070 37.797
201503 23.877 99.621 31.584
201506 20.295 100.684 26.562
201509 17.172 100.392 22.540
201512 -41.206 99.792 -54.413
201603 0.000 100.470 0.000
201606 14.664 101.688 19.003
201609 0.000 101.861 0.000
201612 -106.715 101.863 -138.053
201703 25.730 102.862 32.963
201706 19.531 103.349 24.903
201709 12.330 104.136 15.603
201712 8.999 104.011 11.401
201803 11.122 105.290 13.920
201806 8.255 106.317 10.232
201809 4.508 106.507 5.578
201812 6.240 105.998 7.758
201903 7.666 107.251 9.419
201906 4.767 108.070 5.813
201909 2.299 108.329 2.797
201912 -0.723 108.420 -0.879
202003 5.018 108.902 6.072
202006 10.013 108.767 12.131
202009 8.907 109.815 10.688
202012 7.820 109.897 9.377
202103 6.432 111.754 7.584
202106 5.008 114.631 5.757
202109 13.300 115.734 15.144
202112 12.216 117.630 13.685
202203 11.159 121.301 12.123
202206 9.434 125.017 9.944
202209 7.077 125.227 7.447
202212 5.945 125.222 6.256
202303 2.372 127.348 2.454
202306 3.288 128.729 3.366
202309 2.817 129.860 2.859
202312 2.352 129.419 2.395
202403 1.850 131.776 1.850

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Leap Therapeutics  (NAS:LPTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Leap Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.345/7
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Leap Therapeutics was 1.13. The lowest was 0.17. And the median was 0.42.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Leap Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Leap Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Leap Therapeutics (Leap Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
Executives
Jason Baum officer: Chief Scientific Officer LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Patricia A. Martin director 316 BEECHWOOD FARM LANE, INDIANAPOLIS IN 46260
Christian M Richard director 100 FEDERAL STREET, 19TH FLOOR, BOSTON MA 02110
Richard Schilsky director LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1, CAMBRIDGE MA 02141
Beigene, Ltd. 10 percent owner C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christine Granfield officer: VP, Head of Reg Affairs/Qual C/O LEAP THERAPEUTICS, 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
John Mark O'mahony officer: Chief Manufacturing Officer C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Cynthia Sirard officer: Chief Medical Officer C/O LEAP THERAPEUTICS, INC., 47 THORNDIKE STREET, SUITE B1-1, CAMBRIDGE MA 02141
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Christopher Mirabelli director, 10 percent owner, officer: CEO,Pres,Chairman of the Board 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Augustine Lawlor 10 percent owner, officer: Chief Operating Officer 55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Douglas E Onsi 10 percent owner, officer: CFO,Gen Counsel,Treas, Sec. C/O TOLERRX INC, 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Healthcare Ventures Ix, L.p. 10 percent owner 55 CAMBRIDGE PARKWAY, SUITE 102, CAMBRIDGE MA 02142